DelveInsight Business Research LLP

DelveInsight’s ‘Acromegaly – Market Insights, Epidemiology, and Market Forecast – 2032’ report delivers an in-depth understanding of Acromegaly historical and forecasted epidemiology as well as the Acromegaly market trends in the United States, EU4 (Germany, France, Italy, and Spain), the UK, and Japan.

The Acromegaly market report provides current treatment practices, emerging drugs, market share of individual therapies, and the current and forecasted 7MM Acromegaly market size. The report also covers the Acromegaly procedure, SWOT analysis, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.

Acromegaly Key Highlights 

• The Key Companies working in the Substance Use Disorder market are as follows Crinetics Pharmaceutical, Camurus AB, and many others 

• The Key Therapies working in the Substance Use Disorder market are MYCAPSSA (octreotide acetate), Signifor LAR  (pasireotide), and many others 

• The CAGR of the Acromegaly market is expected to be XX%.

The market size of the Acromegaly market is USD XX Million by 2032.

Acromegaly Overview

Acromegaly is a rare, slowly progressive, acquired disorder that affects adults. The pituitary gland produces too much growth hormone (GH). The pituitary gland is a small gland located near the base of the skull that stores several hormones and releases them into the bloodstream as needed by the body. These hormones regulate many different bodily functions. In most patients, acromegaly is caused by the growth of a benign tumor (adenoma) arising from the pituitary gland. Symptoms of acromegaly include abnormal enlargement in the hands, arms, feet, legs, and head bones. Enlargement of the bones in the jaws and the front of the skull are typically the most apparent bony changes.

 Acromegaly Epidemiology Insights

• In 2022, the total diagnosed prevalent cases of Acromegaly in the United States were ~27,000 cases, which are anticipated to increase by 2032.

• EU4 and the UK accounted for ~21,000 diagnosed prevalent cases of Acromegaly in 2022, which is anticipated to increase by 2032.

• In Japan, tumor origin-specific cases of Acromegaly were ~9,100 and ~480 for pituitary and non-pituitary tumors, respectively, in 2022, which are likely to increase by 2032.

• In EU4 and the UK, tumor size-specific cases of acromegaly were ~18,300 and ~3,050 for macroadenomas and microadenomas, respectively, in 2022, which are likely to increase by 2032.

Click here to learn more about the Acromegaly Market Landscape

The Report Covers the Acromegaly  Epidemiology Segmented by:

• Total Acromegaly incident cases 

• Total Acromegaly prevalent cases 

• Total Acromegaly treatment cases 

• Total Acromegaly diagnostic cases 

Acromegaly Market Outlook 

Acromegaly can start at any time after puberty. However, it occurs more often in middle age, and people are not always aware of their condition. Changes to the body may take place slowly over many years. Although acromegaly is treatable in most people, as symptoms gradually develop, health problems can develop before the disorder is diagnosed and treated.

The current treatment options include surgery, medicines, and radiation therapy. The treatment goals are to control tumor size, return GH and IGF-I levels to normal, improve symptoms, and manage related health problems. Currently, three types (Somatostatin analogs, dopamine agonists, and growth hormone-receptor antagonists) of medicines are used to treat acromegaly. However, they do not provide a cure for the disease. The medicines may be used alone or in combination with each other. The third treatment option is radiation therapy (stereotactic and conventional), which uses high-energy x-rays or particle waves to kill tumor cells. This type of treatment may be recommended if surgery is impossible or fails to remove all tumor tissue, and medicines are not an option.

Key Companies Working in the Acromegaly Market

• Crinetics Pharmaceuticals

• Camurus AB

And many others.

Acromegaly Therapies Covered and Analyzed in the Report:

• MYCAPSSA

• SIGNIFOR LAR (pasireotide)

And many others

 Learn more about the Key Companies and Emerging Therapies in the Acromegaly Market

 Table of Contents 

1. Key Insights 

2. Acromegaly  Introduction 

3. Executive Summary of Acromegaly         

4. Disease Background and Overview

5. Epidemiology and patient population

6. Acromegaly  Emerging Therapies

7. Acromegaly  Market Outlook

8. Market Access and Reimbursement of Therapies

9. Market Drivers 

10. Market Barriers 

11. Appendix

12. Report Methodology

13. DelveInsight Capabilities

14. Disclaimer

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Adya Kaul
Email: Send Email
Phone: 919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services